SCHEMBL6010804

SCHEMBL6010804

CC1(CN2CCN(C(=O)O)[C@H](Cc3ccc(F)cc3)C2)Cn2cc([N+](=O)[O-])nc2O1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.55
CACNA1C Q13936 1/20 0.55
SCN5A Q14524 1/20 0.55
PTGS1 P23219 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SOS1 Q07889 1/20 0.35
CHRM1 P11229 1/20 0.33
KCNJ1 P48048 1/20 0.32
CCR3 P51677 4/20 0.31
CYP2D6 P10635 3/20 0.31
LMNA P02545 1/20 0.30
HTT P42858 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA4 P22748 1/20 0.30
CA9 Q16790 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6010799 1.00 KCNH2 (0.55) KCNH2CACNA1CSCN5APTGS1SLC6A2
SCHEMBL6010920 0.92 KCNH2 (0.46) KCNH2CACNA1CSCN5APTGS1SLC6A2
Hydrochloric Acid SCHEMBL14774897 0.92 KCNH2 (0.47) KCNH2CACNA1CSCN5APTGS1SLC6A2
SCHEMBL6010642 0.91 KCNH2 (0.46) KCNH2CACNA1CSCN5APTGS1SLC6A2
SCHEMBL6010648 0.91 KCNH2 (0.46) KCNH2CACNA1CSCN5APTGS1SLC6A2
SCHEMBL14775037 0.91 KCNH2 (0.45) KCNH2CACNA1CSCN5APTGS1SLC6A2
SCHEMBL14775199 0.91 KCNH2 (0.45) KCNH2CACNA1CSCN5APTGS1SLC6A2
SCHEMBL6010969 0.89 KCNH2 (0.59) KCNH2CACNA1CSCN5APTGS1SLC6A2
SCHEMBL6010973 0.89 KCNH2 (0.59) KCNH2CACNA1CSCN5APTGS1SLC6A2
SCHEMBL14774954 0.88 KCNH2 (0.43) KCNH2CACNA1CSCN5APTGS1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KCNH2 3503/4885CACNA1C 3762/4885SCN5A 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.